Sugi Predict

Sugi Predict / Compounds / SCHEMBL634084

SCHEMBL634084

SCHEMBL634084

Cc1ccccc1S(=O)(=O)NC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NSD2 O96028 2/20 0.51
▸ ALDH1A1 P00352 5/20 0.47
▸ TP53 P04637 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ LMNA P02545 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ EDNRA P25101 2/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ PARG Q86W56 1/20 0.46
▸ SLC1A3 P43003 1/20 0.45
▸ SLC1A2 P43004 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2803354 0.87 NSD2 (0.58) NSD2ALDH1A1LMNAMAPTKMT2A
SCHEMBL13483650 0.81 NSD2 (0.68) NSD2ALDH1A1LMNAMAPTKMT2A
SCHEMBL6927887 0.80 EDNRA (0.54) ALDH1A1TP53TDP1LMNAMAPT
SCHEMBL14676076 0.80 SLC1A3 (0.50) ALDH1A1TP53TDP1LMNAKDM4E
SCHEMBL23345388 0.79 NSD2 (0.51) NSD2ALDH1A1LMNAMAPTKMT2A
SCHEMBL13075810 0.79 NSD2 (0.51) NSD2ALDH1A1LMNAMAPTKMT2A
SCHEMBL30338563 0.78 LMNA (0.57) ALDH1A1TP53TDP1LMNAMAPT
SCHEMBL634340 0.78 LMNA (0.57) ALDH1A1TP53TDP1LMNAMAPT
SCHEMBL264098 0.78 CA1 (0.52) NSD2LMNAMAPTKMT2AKDM4E
SCHEMBL2893576 0.78 NSD2 (0.50) NSD2ALDH1A1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106458992-B Pyridyl piperidine 默克专利股份公司 2019-03-15 — — CN disclosed
EP-2078003-B1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME (US) 2017-03-08 — — EP disclosed
EP-2302000-B1 CURABLE COMPOSITION AND CATALYST COMPOSITION KANEKA CORP (JP) 2016-11-16 — — EP disclosed
US-9226505-B2 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-05 — — US disclosed
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 — — US disclosed
US-9139609-B2 C-4″ position substituted macrolide derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-22 — — US disclosed
US-9051501-B2 Curable composition and catalyst composition KANEKA CORPORATION (JP) 2015-06-09 — — US disclosed
US-20140329684-A1 USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-11-06 — — US disclosed
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-02-13 — — US disclosed
US-20130177529-A1 Pyrazole Compounds VIVOQUEST, INC. 2013-07-11 — — US disclosed
US-7820675-B2 Benzofuran compounds BIOVITRUM AB (SE) 2010-10-26 — — US disclosed
US-20100063215-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-03-11 — — US disclosed
US-7674810-B2 1,1-dioxo-1H-1Λ6-benzo[d]isothiazol-3-yl)-4-hydroxy-1,5-dihydro-pyrrol-2-one inhibitors of HCV polymerase ROCHE PALO ALTO LLC (US) 2010-03-09 — — US disclosed
US-20100041810-A1 CURABLE COMPOSITION AND CATALYST COMPOSITION KANEKA CORPORATION (JP) 2010-02-18 — — US disclosed
EP-2100923-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2009-09-16 — — EP disclosed
EP-2088173-A1 CURABLE COMPOSITION AND CATALYST COMPOSITION Kaneka Corporation (JP) 2009-08-12 — — EP disclosed
US-7247725-B2 Gamma-aminoamide modulators of chemokine receptor activity MERCK & CO., INC. (US) 2007-07-24 — — US disclosed
EP-0475707-B1 Hot-melt ink composition SEIKO EPSON CORP (JP) 1995-03-22 — — EP disclosed
US-5230731-A (Di)alkylbenzenesulfonamide SEIKO EPSON CORPORATION (JP) 1993-07-27 — — US disclosed
EP-0475707-A2 Hot-melt ink composition SEIKO EPSON CORPORATION (JP) 1992-03-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329684-A1 USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS HPD, HSF1, PDK4 NSD2 4342/4885ALDH1A1 139/4885TP53 2653/4885
US-20130177529-A1 Pyrazole Compounds MAVS, EIF2AK2, ZC3HAV1 NSD2 1345/4885ALDH1A1 1769/4885TP53 520/4885
US-20140046043-A1 C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE MRPL21, MRPS34, MRPL37 NSD2 2039/4885ALDH1A1 4667/4885TP53 4224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.